vs
Ascendis Pharma A/S（ASND）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是Ecovyst Inc.的1.3倍（$267.3M vs $199.4M），Ascendis Pharma A/S同比增速更快（42.3% vs 34.0%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs 18.7%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
ASND vs ECVT — 直观对比
营收规模更大
ASND
是对方的1.3倍
$199.4M
营收增速更快
ASND
高出8.3%
34.0%
两年增速更快
ASND
近两年复合增速
18.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $199.4M |
| 净利润 | — | — |
| 毛利率 | 90.5% | 23.4% |
| 营业利润率 | — | 10.9% |
| 净利率 | — | — |
| 营收同比 | 42.3% | 34.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDECVT
| Q4 25 | $267.3M | $199.4M | ||
| Q3 25 | $230.7M | $204.9M | ||
| Q2 25 | $170.7M | $176.1M | ||
| Q1 25 | $109.0M | $143.1M | ||
| Q4 24 | $187.8M | $148.9M | ||
| Q3 24 | $62.5M | $153.9M | ||
| Q2 24 | $38.9M | $154.0M | ||
| Q1 24 | $103.6M | $141.6M |
净利润ASNDECVT
| Q4 25 | — | — | ||
| Q3 25 | $-65.9M | $-79.3M | ||
| Q2 25 | $-42.0M | $6.0M | ||
| Q1 25 | $-102.2M | $-3.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-107.1M | $14.3M | ||
| Q2 24 | $-118.1M | $8.3M | ||
| Q1 24 | $-141.5M | $1.2M |
毛利率ASNDECVT
| Q4 25 | 90.5% | 23.4% | ||
| Q3 25 | 89.5% | 25.4% | ||
| Q2 25 | 80.1% | 22.8% | ||
| Q1 25 | 82.6% | 13.3% | ||
| Q4 24 | 91.9% | 28.9% | ||
| Q3 24 | 80.6% | 29.3% | ||
| Q2 24 | 68.2% | 27.3% | ||
| Q1 24 | 92.1% | 23.5% |
营业利润率ASNDECVT
| Q4 25 | — | 10.9% | ||
| Q3 25 | 5.1% | 13.8% | ||
| Q2 25 | -33.5% | 9.0% | ||
| Q1 25 | -103.2% | -0.7% | ||
| Q4 24 | — | 15.1% | ||
| Q3 24 | -167.3% | 17.9% | ||
| Q2 24 | -370.2% | 14.1% | ||
| Q1 24 | -51.2% | 9.5% |
净利率ASNDECVT
| Q4 25 | — | — | ||
| Q3 25 | -28.5% | -38.7% | ||
| Q2 25 | -24.6% | 3.4% | ||
| Q1 25 | -93.7% | -2.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -171.5% | 9.3% | ||
| Q2 24 | -303.9% | 5.4% | ||
| Q1 24 | -136.6% | 0.9% |
每股收益（稀释后）ASNDECVT
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $-0.69 | ||
| Q2 25 | — | $0.05 | ||
| Q1 25 | — | $-0.03 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $197.2M |
| 总债务越低越好 | — | $392.6M |
| 股东权益账面价值 | $-175.8M | $603.4M |
| 总资产 | $1.4B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资ASNDECVT
| Q4 25 | $665.3M | $197.2M | ||
| Q3 25 | $582.2M | $82.0M | ||
| Q2 25 | $533.6M | $69.6M | ||
| Q1 25 | $559.4M | $127.5M | ||
| Q4 24 | $604.3M | $131.4M | ||
| Q3 24 | $675.6M | $123.5M | ||
| Q2 24 | $279.4M | $83.3M | ||
| Q1 24 | $345.9M | $103.1M |
总债务ASNDECVT
| Q4 25 | — | $392.6M | ||
| Q3 25 | — | $854.8M | ||
| Q2 25 | — | $856.6M | ||
| Q1 25 | — | $859.0M | ||
| Q4 24 | — | $860.8M | ||
| Q3 24 | — | $862.7M | ||
| Q2 24 | — | $862.4M | ||
| Q1 24 | — | $866.2M |
股东权益ASNDECVT
| Q4 25 | $-175.8M | $603.4M | ||
| Q3 25 | $-188.0M | $607.9M | ||
| Q2 25 | $-202.6M | $692.4M | ||
| Q1 25 | $-205.0M | $698.7M | ||
| Q4 24 | $-114.2M | $700.5M | ||
| Q3 24 | $-105.1M | $729.4M | ||
| Q2 24 | $-346.8M | $717.3M | ||
| Q1 24 | $-257.2M | $711.4M |
总资产ASNDECVT
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | $819.0M | $1.8B | ||
| Q1 24 | $866.7M | $1.8B |
负债/权益比ASNDECVT
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $41.8M |
| 自由现金流经营现金流 - 资本支出 | — | $22.9M |
| 自由现金流率自由现金流/营收 | — | 11.5% |
| 资本支出强度资本支出/营收 | — | 9.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $69.9M |
8季度趋势，按日历期对齐
经营现金流ASNDECVT
| Q4 25 | $58.2M | $41.8M | ||
| Q3 25 | — | $55.3M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | $-15.5M | $10.3M | ||
| Q4 24 | $-330.7M | $43.5M | ||
| Q3 24 | — | $59.9M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | $-109.7M | $36.5M |
自由现金流ASNDECVT
| Q4 25 | — | $22.9M | ||
| Q3 25 | — | $53.2M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $-14.0M | ||
| Q4 24 | — | $30.9M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | — | $-9.3M | ||
| Q1 24 | — | $19.1M |
自由现金流率ASNDECVT
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 26.0% | ||
| Q2 25 | — | 4.4% | ||
| Q1 25 | — | -9.8% | ||
| Q4 24 | — | 20.7% | ||
| Q3 24 | — | 34.9% | ||
| Q2 24 | — | -6.1% | ||
| Q1 24 | — | 13.5% |
资本支出强度ASNDECVT
| Q4 25 | — | 9.4% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 14.4% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 12.3% |
现金转化率ASNDECVT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.21× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 29.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
